Sign Up
OverviewAPI
Hansa Biopharma reports a 90% patient survival rate and 82% graft survival rate at five years post-transplant for highly sensitized patients receiving a kidney transplant following desensitization with imlifidase. Calliditas Therapeutics presents positive data from the NefIgArd Phase 3 trial, showing that Nefecon treatment slows kidney function decline in adults with IgA nephropathy. The study highlights the central role of the gut-kidney axis in the pathogenesis of IgA nephropathy.

Ask a question